Bridgeway Capital Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bridgeway Capital Management’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-32,100	Closed	-$531K	–	1396
2019 Q2	$531K	Sell	32,100 -37,000	-54%	-$604K	0.01%	958
2019 Q1	$1.2M	Hold	69,100	–	–	0.01%	695
2018 Q4	$1.22M	Hold	69,100	–	–	0.02%	658
2018 Q3	$1.25M	Hold	69,100	–	–	0.01%	792
2018 Q2	$1.35M	Hold	69,100	–	–	0.01%	759
2018 Q1	$1.21M	Hold	69,100	–	–	0.01%	782
2017 Q4	$784K	Hold	69,100	–	–	0.01%	939
2017 Q3	$736K	Hold	69,100	–	–	0.01%	959
2017 Q2	$605K	Buy	69,100 +30,800	+80%	+$271K	0.01%	1029
2017 Q1	$452K	Hold	38,300	–	–	0.01%	1099
2016 Q4	$502K	Hold	38,300	–	–	0.01%	1089
2016 Q3	$555K	Buy	+38,300	New	+$544K	0.01%	1045

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's CBMG Position: Q3 2019 in Review

Bridgeway Capital Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2019, closing a stake of 32,100 shares — an estimated $531K sold.

Bridgeway Capital Management first reported a position in CBMG in Q3 2016 and held it in 12 quarters. The position peaked at $1.35M in Q2 2018. 40 funds tracked by Wall St. Rank hold CBMG as of Q3 2019.

Bridgeway Capital Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2019 after selling out during the quarter.
Bridgeway Capital Management sold 32,100 Cellular Biomedicine Group, Inc. shares in Q3 2019, an estimated $531K.
Bridgeway Capital Management first reported a position in Cellular Biomedicine Group, Inc. in Q3 2016 and held it in 12 quarters.
Bridgeway Capital Management's Cellular Biomedicine Group, Inc. position peaked at $1.35M in Q2 2018.
40 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2019.

Based on Bridgeway Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.